YiLinCloud Files IPO Prospectus: Building an Integrated Intelligent Cloud Platform to Address Digital Transformation Challenges in Clinical Trials

There has been a significant gap in the digitalization of clinical trials in China.

Under the dual pressures of policy and market forces, the pharmaceutical industry is focusing on optimizing sales models and enhancing R&D efficiency. Medical SaaS vendors are developing products by collecting and integrating data flows and accumulating substantial data sets from these two areas, aiming to improve the success rate of clinical drug development, enhance the quality of clinical trials, and shorten the R&D cycle.

On one hand, the Chinese market has long been dominated by foreign pharmaceutical R&D SaaS vendors represented by Medidata, Veeva, and Oracle, with a lack of pharmaceutical R&D SaaS solutions that can truly address the needs of local pharmaceutical companies and deeply understand their pain points. On the other hand, in China’s digital clinical research industry, while many vendors focus on specific segments, few enterprises are capable of providing truly integrated solutions.

Yi Lin Yun (Shenzhen) Technology Co., Ltd. (hereinafter referred to as “Yi Lin Yun”) is positioned as an integrated SaaS cloud platform for clinical evidence support., striving to build upon existing solutions; meanwhile, as a strategic partner of Signant Health, an international company providing clinical evidence support, it is responsible for the comprehensive operation of business in Greater China. It promotes eCOA (electronic Clinical Outcome Assessment) software and services based on customer needs.

It is reported that its eCOA solution has been deployed in more than 2,500 clinical trials worldwide, covering approximately 1 million patients and serving over 1,000 institutions.

Generally speaking, the pharmaceutical R&D SaaS industry is one that emphasizes user reputation. Leading companies can easily leverage accumulated user needs to rapidly iterate their products, thereby achieving a snowball effect. Consequently, resources in the pharmaceutical R&D SaaS sector tend to concentrate among the top players.

However, the startup Yilin Cloud has, within a short period of time,Developed an integrated SaaS solution for pharmaceutical R&D, leveraging a unified platform to address industry-wide challenges such as information silos, the inability to transcribe data across different systems, and low accuracy in manual verification, thereby further enhancing the efficiency of clinical research.At the same time, it further lays the foundation for big data analytics across applications, projects, and users.

In the view of Qin Long, founder of Yilin Cloud, the development path of entering certain key links and then extending forward and backward can easily cause pharmaceutical R&D SaaS companies to face challenges such as insufficient synergy between new and old services in the process of expanding their service scope, and the difficulty of achieving system and data interconnectivity in the final solution. Therefore,For pharmaceutical R&D SaaS companies, “beginning with the end in mind” is the optimal development strategy to overcome this challenge.

Qin Long further explained that“To help pharmaceutical companies obtain reliable clinical endpoint assessment results, pharmaceutical R&D SaaS providers must address the entire new drug development process, including data generation, data collection, and data analysis. Meanwhile, they should build a comprehensive product architecture based on stringent regulatory requirements to help clients achieve solutions that are as consistent as possible with clinical endpoint outcomes. It is also crucial to anticipate future system interoperability during this process; companies need not only to expand their product coverage but also to maintain unified data standards and ensure seamless data connectivity.”

Guided by this understanding, Yilin Cloud aims to ultimately establish an integrated, data-driven, patient-centric SaaS platform for clinical evidence support, thereby genuinely enhancing the efficiency of pharmaceutical companies’ clinical research.

The company has completed the development of its integrated platform, which is now mature and has been validated through hundreds of projects.Moving forward, Lin Yun will continue to build upon this foundation by developing the DCT platform, enabling remote processes ranging from patient informed consent, data collection, and project technology implementation to physicians’ endpoint assessments.

It is understood that Lin Yun has completed the overall system architecture centered on the eCOA system at this stage.

Yi Lin Yun’s eCOA system provides pharmaceutical companies with a comprehensive library of standardized scales while supporting complex logical checks. By leveraging the interrelationships among questions across scales, it helps raters promptly identify data anomalies. Additionally, sponsors, CROs, and research centers can access and review data in real time through multidimensional reporting tools.

RTSM (Randomization and Trial Supply Management), MAMS (Medical Asset Management System), and CTMS (Clinical Trial Management System) can assist pharmaceutical companies in managing clinical trial projects.

Moreover, Yilin Cloud also provides pharmaceutical companies with related supporting services, including scale management, rater training and qualification certification, as well as study design and configuration.to address issues faced by pharmaceutical companies during the final product approval process, such as lack of copyright acquisition for scales, digitalization of scales, and subjectivity in scale results.

With the support of international experts, Yilin Cloud will also add new modules such as Sensor Link (wearable device data acquisition) and eConsent (electronic informed consent) to its existing products.Further optimize enterprise solutions. Expand business operations in scale-based services, backend medical support, rater training, and endpoint assessment for multi-center clinical trials.

For example, by leveraging modules such as wearable devices and electronic informed consent forms, patient data can be transmitted directly to the Yilin Cloud system via connected devices, eliminating the need for patients to manually enter information. This further ensures the accuracy and objectivity of patient data. Additionally, features like electronic informed consent and remote monitoring systems enable companies to better engage with patients.

Meanwhile, Yilin Cloud also plans to complete the construction of its “data-driven” business platform by the end of 2024, delivering applications that unlock data value for customers, expanding the breadth and depth of its products, and transforming the Yilin Cloud business platform into a truly intelligent platform.

In this regard, Qin Long stated:“Achieving true data interoperability is extremely challenging, yet it remains the most significant hurdle faced by nearly all pharmaceutical companies today. Therefore, Yilin Cloud aims to achieve this goal through a ‘data-driven’ approach. Specifically, it leverages an integrated platform system to acquire authentic and reliable patient data, operational data, and industry data. These three categories of data are then used to assist pharmaceutical companies in obtaining more precise clinical endpoint assessments and conducting clinical projects using digital methods.”

To truly help clients achieve more precise clinical endpoint assessments, ultimately improving the success rate of clinical drug development, enhancing the quality of clinical trials, and shortening the R&D cycle, Yilin Cloud has assembled a team with profound expertise in clinical research and established an independent Medical Affairs Department. This department provides specialized support, including regulatory and legal guidance, for new drug development. It enables enterprises to build platforms, underlying architectures, and product functionalities that comply with the regulatory requirements of health authorities worldwide from the very outset of product design.

Dr. Qin Long, Founder of Yilin Cloud, boasts over 16 years of experience in the application of technology within the clinical research industry. He pioneered the promotion and implementation of digital clinical solutions in China’s clinical trial research sector. Previously, as the Head of Business Development for Signant Health in the Asia-Pacific region, he spearheaded strategic business growth in the area. Following his departure to launch his own venture, Signant Health entrusted Dr. Qin with oversight of its Asia-Pacific operations—a testament to the strong mutual trust between both parties.

Qin Long told VCBeat:“The partnership with Signant Health has strengthened Yilinyun’s competitive edge in its international operations. Yilinyun’s platform design, product functionalities, and delivery standards are all established in accordance with international benchmarks, laying a solid foundation for the company to meet broader market demands in the future.”

The Chief Technology Officer of Yilin Cloud boasts over 30 years of experience in IT technology within the healthcare, finance, and manufacturing sectors. He has previously held C-level executive positions at major corporations such as Oracle, Hitachi Data Systems, and IBM, and possesses extensive expertise in IT infrastructure and SaaS platform development.

The Chief Medical Officer has over 17 years of experience in medicine, clinical operations, and quality management within the field of clinical research. Previously, he/she led a team at a renowned innovative pharmaceutical company to formulate and implement the global clinical development strategy for core products, successfully achieving market approval in both China and the United States. He/She is well-versed in commonly used electronic systems for clinical trials, both domestically and internationally, such as EDC, CTMS, eTMF, and eCOA.

The medical expertise of the Yilin Cloud team further sets it apart from its peers in the same sector.

Yi Lin Yun’s medical team understands the seriousness of clinical research and clearly identifies areas where sponsors can improve clinical trial efficiency, thereby reducing the risk of drug development failure.Therefore, Yilin Cloud’s products are naturally better aligned with real-world clinical research scenarios, helping pharmaceutical and medical device companies truly reduce costs and improve efficiency, shorten drug development cycles, and increase the success rate of drug development. After two years of dedicated refinement, Yilin Cloud has begun to support relevant projects and enterprise product research.

Over the past five years, Chinese pharmaceutical companies have increasingly prioritized and conducted extensive post-marketing studies. However, the vast majority of these enterprises have not standardized, cleaned, or integrated the data generated from such studies. In contrast, international giants like Pfizer invest substantial funds annually in standardizing clinical research data to maximize product value and extend product lifecycles. This underscores that the adoption of digital and intelligent approaches in new drug development is an inevitable trend for the future.

The implementation of policies such as the “4+7” volume-based procurement, consistency evaluation, and DRG-based medical insurance cost containment has further compelled pharmaceutical companies to accelerate the digital transformation of clinical research. At this critical juncture of industrial upgrading in the pharmaceutical sector, the market demands pharmaceutical R&D SaaS solutions that can genuinely address the needs of pharmaceutical enterprises and deeply understand their pain points. Yilin Cloud has built a patient-centric, integrated SaaS cloud platform for clinical evidence support, guided by technological innovation and precision medicine evaluation frameworks, which holds significant value.

In the future, Yilin Cloud will also establish long-term business collaborations with major biotechnology companies, CROs, large pharmaceutical companies, small and medium-sized pharmaceutical companies, and multinational corporations to build an industry ecosystem, further expand business channels, and rapidly achieve comprehensive industry coverage.